Lapatinib, a dual kinase inhibitor that targets HER2 and EGFR and is used to treat patients with HER2-positive breast cancer, was found to be more effective at promoting cell death and inhibiting proliferation when combined with NSC668394 [131]. This evidence concerns the gene ERBB2 and breast cancer.